Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell surface glycoprotein CD3 zeta chain, encoded by the CD247 gene, is a fundamental transmembrane component of the T-cell receptor (TCR)-CD3 complex [2, 6]. It is distinguished by the presence of three immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain, which are essential for converting extracellular antigen recognition into intracellular signals [6, 20]. Upon TCR engagement, these ITAMs are phosphorylated by Src family kinases, such as Lck, which facilitates the recruitment and activation of ZAP-70 kinase [1, 20]. This process initiates critical downstream pathways that drive T-cell differentiation, proliferation, and the adaptive immune response [6, 10]. In modern immunotherapy, the CD3 zeta chain is the cornerstone of chimeric antigen receptor (CAR) design, providing the primary activation signal for FDA-approved therapies like Tisagenlecleucel and Axicabtagene ciloleucel [4, 17]. Reduced expression or dysfunction of this protein is a known mechanism of immune evasion in various cancers and chronic infections, making it a significant biomarker for immune competence [14, 16]. Additionally, genetic defects in the CD247 locus are associated with severe combined immunodeficiency and autoimmune conditions [10, 11].
The CD3 zeta chain functions as the primary signal transducer for the T-cell receptor complex. Upon antigen binding, its immunoreceptor tyrosine-based activation motifs (ITAMs) are phosphorylated by Lck and Fyn kinases, which creates docking sites for ZAP-70. This recruitment triggers downstream signaling cascades, including the PLC-gamma1 and Ras/MAPK pathways, leading to T-cell activation, cytokine secretion, and cytotoxic activity [1, 6, 20].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell surface glycoprotein CD3 zeta chain (CD3ζ) (CD3ζ).